Jury rules Prempro caused woman’s breast cancer

Share this article:
A Philadelphia jury found on Tuesday that Wyeth’s hormone replacement therapy Prempro was the cause of a woman’s breast cancer and awarded her and her husband damages of $3 million. Wyeth said it plans to appeal the decision. “We respectfully disagree that there is any scientific basis to support the jury’s finding of a causal link between Wyeth’s hormone therapies and the plaintiff’s breast cancer,” said Barbara Binis, an attorney representing Wyeth in the case. A previous Philadelphia jury also found in favor of the plaintiff, Jennie Nelson in October. However the judge threw out that verdict and declared a mistrial, leading to the trial that concluded yesterday. The original jury had awarded Nelson and her husband $1.5 million in compensatory damages. This time Nelson was awarded $2.4 million and her husband $600,000. The reason for the mistrial was not disclosed however there has been speculation since that it may have been overturned as a result of juror misconduct. Wyeth is facing approximately 5,000 lawsuits over its hormone replacement therapies. The drugs remain on the market despite a major government-sponsored study that found using them for five years or more can increase the risk of breast cancer.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.